More Data Needed to Make Decision on Bardoxolone in Alport Syndrome
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Reata Pharmaceuticals regarding the New Drug Application (NDA) for bardoxolone for the treatment of patients with chronic kidney disease (CKD) caused…